Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma

Immunology Letters

Volumn 123, Issue 1, 2009, Pages 31-37

  Stahl, Simone ^a   Sacher, Torsten ^a   Bechtold, Astrid ^a   Protzer, Ulrike ^b   Ganss, Ruth ^a   Hämmerling, Günter J ^a   Arnold, Bernd ^a   Garbi, Natalio ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Immunotherapy; Inducible hepatoma model; Tumor tolerance

Indexed keywords

ONCOPROTEIN; TAG PEPTIDE; UNCLASSIFIED DRUG; VIRUS T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EXPERIMENTAL MODEL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINATION;

ALBUMINS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; IMMUNE TOLERANCE; LIVER NEOPLASMS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 63749092190     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2009.01.011     Document Type: Article

References (51)

1. Pardoll D. Does the immune system see tumors as foreign or self?. Annu Rev Immunol 21 (2003) 807-839
2. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5 (1999) 677-685
3. Romero P., Dunbar P.R., Valmori D., Pittet M., Ogg G.S., Rimoldi D., et al. ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 188 (1998) 1641-1650
4. Nguyen L.T., Elford A.R., Murakami K., Garza K.M., Schoenberger S.P., Odermatt B., et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 195 (2002) 423-435
5. Garbi N., Arnold B., Gordon S., Hammerling G.J., and Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol 172 (2004) 5861-5869
6. Greenberg P.D. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49 (1991) 281-355
7. Bremers A.J., and Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol 34 (2000) 1-25
8. Cranmer L.D., Trevor K.T., and Hersh E.M. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53 (2004) 275-306
9. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909-915
10. Chen L., Ashe S., Brady W.A., Hellstrom I., Hellstrom K.E., Ledbetter J.A., McGowan P., and Linsley P.S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71 (1992) 1093-1102
11. + T cells by B7-transfected melanoma cells. Science 259 (1993) 368-370
12. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., and Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 5 (1999) 774-779
13. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096-1103
14. Tada T., Ohzeki S., Utsumi K., Takiuchi H., Muramatsu M., Li X.F., et al. Transforming growth factor-β-induced inhibition of T cell function Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 146 1 (1991) 1077-1082
15. Alleva D.G., Burger C.J., and Elgert K.D. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol 153 (1994) 1674-1686
16. Vasmel W.L., Sijts E.J., Leupers C.J., Matthews E.A., and Melief C.J. Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens. J Exp Med 169 (1989) 1233-1254
17. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
18. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18 (1997) 89-95
19. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
20. Nanda N.K., and Sercarz E.E. Induction of anti-self-immunity to cure cancer. Cell 82 (1995) 3-17
21. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186 (1997) 645-653
22. Ochsenbein A.F., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 96 (1999) 2233-2238
23. Valmori D., Fonteneau J.F., Valitutti S., Gervois N., Dunbar R., Lienard D., et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol 11 (1999) 1971-1980
24. Pinilla C., Rubio-Godoy V., Dutoit V., Guillaume P., Simon R., Zhao Y., et al. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res 61 (2001) 5153-5160
25. Saha A., Chatterjee S.K., Foon K.A., Celis E., and Bhattacharya-Chatterjee M. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Cancer Res 67 (2007) 2881-2892
26. Jonkers J., and Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2 (2002) 251-265
27. Lou D.Q., Molina T., Bennoun M., Porteu A., Briand P., Joulin V., et al. Conditional hepatocarcinogenesis in mice expressing SV 40 early sequences. Cancer Lett 229 (2005) 107-114
28. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15 (2001) 3243-3248
29. Meuwissen R., Linn S.C., Linnoila R.I., Zevenhoven J., Mooi W.J., and Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4 (2003) 181-189
30. Tevethia S.S. Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. Mol Biol Med 7 (1990) 83-96
31. Tilghman S.M., and Belayew A. Transcriptional control of the murine albumin/α-fetoprotein locus during development. Proc Natl Acad Sci U S A 79 (1982) 5254-5257
32. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315 (1985) 115-122
33. Ganss R., Ryschich E., Klar E., Arnold B., and Hammerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62 (2002) 1462-1470
34. Garbi N., Tan P., Diehl A.D., Chambers B.J., Ljunggren H.G., Momburg F., et al. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol 1 (2000) 234-238
35. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 (1999) 77-92
36. Schell T.D., Knowles B.B., and Tevethia S.S. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res 60 (2000) 3002-3012
37. Aichele P., Brduscha-Riem K., Oehen S., Odermatt B., Zinkernagel R.M., Hengartner H., et al. Peptide antigen treatment of naive and virus-immune mice: antigen-specific tolerance versus immunopathology. Immunity 6 (1997) 519-529
38. Feuerer M., Beckhove P., Garbi N., Mahnke Y., Limmer A., Hommel M., et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 9 (2003) 1151-1157
39. Tao N., Gao G.P., Parr M., Johnston J., Baradet T., Wilson J.M., et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3 (2001) 28-35
40. Ferber I., Schonrich G., Schenkel J., Mellor A.L., Hammerling G.J., and Arnold B. Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 263 (1994) 674-676
41. Brockschnieder D., Pechmann Y., Sonnenberg-Riethmacher E., and Riethmacher D. An improved mouse line for Cre-induced cell ablation due to diphtheria toxin A, expressed from the Rosa26 locus. Genesis 44 (2006) 322-327
42. Willimsky G., and Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437 (2005) 141-146
43. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., and Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12 (1994) 337-365
44. Kurts C., Sutherland R.M., Davey G., Li M., Lew A.M., Blanas E., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A 96 (1999) 12703-12707
45. + T cell tolerance to peripherally expressed antigens. J Immunol 163 (1999) 723-727
46. Boon T., Coulie P.G., Van den Eynde B.J., and van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 24 (2006) 175-208
47. Romero P., Cerottini J.C., and Speiser D.E. The human T cell response to melanoma antigens. Adv Immunol 92 (2006) 187-224
48. Muller-Berghaus J., Ehlert K., Ugurel S., Umansky V., Bucur M., Schirrmacher V., et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 66 (2006) 5997-6001
49. b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol 69 (1995) 6665-6677
50. b-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology 171 (1989) 205-213
51. + T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J Virol 74 (2000) 6922-6934